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Introduction
Pentamidine is an anti-protozoical compound used in the treatment of trypanosomiasis, leishmaniasis and Pneumocystis carinii pneumonia that causes drug-induced or acquired long QT syndrome (acLQTS) in clinical use (Bibler et al., 1988; Burchmore et al., 2002; Girgis et al., 1997; Nacher et al., 2001; Sands et al., 1985; Wharton et al., 1987) . AcLQTS produces electrocardiographic abnormalities that have been associated with syncope, torsades de pointes arrhythmias and sudden cardiac death (Kannankeril et al., 2010) and are most often caused by direct block of the cardiac potassium current I Kr /hERG, which is crucial for terminal repolarization in human heart (Sanguinetti and Tristani-Firouzi, 2006) . Because hERG block constitutes an adverse side effect of therapeutic compounds as well as a significant hurdle in the development of novel drug compounds, several preclinical assays have been developed for early detection including binding assays and the so-called hERG assay which consists of patch clamp measurements performed on cloned hERG channels (Pollard et al., 2010; Thomsen et al., 2006) . Importantly, a number of therapeutic compounds exist that go undetected in conventional assays targeting direct hERG block (Dennis et al., 2007; van der Heyden et al., 2008) . For example, we have shown that arsenic trioxide, which is used in the treatment of leukemia (Ficker et al., 2004) , reduces the number of hERG channels at the cell surface by inhibiting the maturation of hERG channels in the endoplasmic reticulum (ER) and preventing export from the ER. At the same time, arsenic trioxide increases cardiac calcium currents via oxidative inactivation of the lipid phosphatase PTEN . Both mechanisms converge to create cardiac repolarization abnormalities which are reflected in a high incidence of adverse cardiac events during therapy (Barbey et al., 2003; Ohnishi et al., 2002; Ohnishi et al., 2000) . Similarly, a large number of direct hERG-blockers provide a double hit on cardiac repolarization in that they combine conventional hERG block with unconventional hERG trafficking inhibition Rajamani et al., 2006; Takemasa et al., 2008; Obers et al., 2010; Staudacher et al., MOL # 75135 5 2011). Unfortunately, few compounds that cause acLQTS by unconventional mechanisms have been fully characterized at the cellular and molecular level.
Dicationic pentamidine is another example of a therapeutic compound that has been associated with a high incidence of cardiac arrhythmias due to a combination of unconventional mechanisms: (1) reduced hERG surface expression and (2) acute block of cardiac inward rectifier channels, which destabilizes the cardiac membrane potential late during repolarization and under resting conditions (Cordes et al., 2005; de Boer et al., 2010; Ficker et al., 2005; Kuryshev et al., 2005) . While a mechanistic model for acute block of cardiac inward rectifier channels by pentamidine has been developed (de Boer et al., 2010 ), the precise mechanisms by which pentamidine interferes with hERG surface expression are unknown. Currently, it is only known that the fully-glycosylated cell surface form of hERG together with the corresponding membrane currents disappear following long-term incubation with pentamidine .
Importantly, pentamidine does not directly block hERG in the therapeutic concentration range (Cordes et al., 2005) .
We focus here on how hERG surface expression is disrupted by pentamidine at the cellular and molecular level. We find that pentamidine exclusively inhibits export of hERG from the endoplasmic reticulum (ER). We show for the first time that pentamidine arrests hERG maturation in a non-exportable conformation via binding to a critical amino acid residue, F656, which contributes to the well-characterized canonical drug binding site in the conduction pathway of terminally folded hERG. We propose that pentamidine may inhibit hERG trafficking by acting as a novel pharmacological entity, namely a small molecule 'anti-chaperone'.
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Materials and Methods
Cell culture
Human embryonic kidney (HEK) 293 cells stably expressing hERG WT (HEK/hERG WT), were maintained at 37 o C, 5% CO 2 in DMEM supplemented with 10% fetal bovine serum, L-glutamine, penicillin/streptomycin (complete DMEM) and G418. Point mutations of hERG were engineered either by overlap extension PCR or using the QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). All mutant constructs were verified by sequencing.
Several different mutant hERG channel cDNAs were gifts from M. Sanguinetti (University of Utah, Salt Lake City, UT) and S. Zhang (Queen's University, Kingston, ON, Canada). Mutant hERG as well as bEAG WT (bovine ether-à-go-go) were transiently expressed in HEK293 cells using FuGENE 6 transfection reagent (Roche Diagnostics, Indianapolis, IN), and compared to transiently transfected hERG WT.
HL-1 cardiomyocytes were maintained as described by Claycomb et al., 1998 . Briefly, HL-1 cells were plated on culture dishes coated with gelatin and fibronectin and maintained at 37°C in an atmosphere of 95 % humidified air and 5 % CO 2 in Claycomb Medium (SigmaAldrich, St. Louis, MO) supplemented with 10 % FBS, 2 mM L-glutamine, 0.1 mM norepinephrine (Sigma-Aldrich), penicillin, and streptomycin. The medium was changed approximately every 24-48 h. When confluent, cells were dissociated using trypsin/EDTA (Invitrogen, Carlsbad, CA) and re-suspended in complete Claycomb Medium at a density of 25 x 10 6 cells/60 mm dish for Western blotting, and at a density of 25,000 cells/gelatin-fibronectin coated coverslip for electrophysiological recordings.
Neonatal rat ventricular myocytes (NRVM) were isolated from dissected hearts of 1-2 day old rat pups as described previously. 
Western blot analysis
A previously described polyclonal anti-hERG antibody, rabbit hERG 519, was used to analyze hERG expression in HEK cells (Ficker et al., 2003) . In HL-1 cardiomyocytes and
NRVMs hERG/I Kr expression was analyzed using a polyclonal anti-hERG-GST antibody from Alomone Labs, Jerusalem, Israel. Briefly, HEK/hERG cells or cardiomyocytes were solubilized for 1 h at 4 o C in lysis buffer containing 150 mM NaCl, 1 mM EDTA, 50 mM Tris, pH 7.5, 1%
Triton X-100 and protease inhibitors (Complete, Roche Diagnostics). Protein concentrations were determined by the BCA method (Pierce, Rockford, IL). Proteins were separated on SDS polyacrylamide gels, transferred to polyvinylidene difluoride membranes and developed using the appropriate anti-hERG antibody followed by horseradish peroxidase-conjugated secondary antibody and ECL Plus (GE Healthcare, Piscataway, NJ). For quantitative analysis, signals were captured directly on a Kodak Imager R4000 (Carestream Health, Rochester, NY).
hERG ubiquitination
In ubiquitination studies, stable HEK/hERG WT cells were transiently transfected with either HA-ubiquitin or His 6 -ubiquitin cDNA using Fugene (Roche Diagnostics). Cells were harvested 2 days after transfection. In experiments with pentamidine, cells were treated overnight on the second day following transfection. Whole cell lysates were immunoprecipitated with antihERG antibody. Immunoprecipitates were analyzed on Western blots using either antibody to hERG or to the HA epitope fused to ubiquitin. Lysates with His 6 -ubiquitin were used as negative control.
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Sucrose gradients
HEK/hERG WT cells (pentamidine treated or untreated controls) were lysed in Digitonin lysis buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1% digitonin and protease inhibitors (Complete, Roche Diagnostics). Soluble material (400-800 μ g total protein) was layered onto 15-45% sucrose gradients (150mM NaCl, 10mM Tris, pH 7.4, 0.1% digitonin). Gradients were made using BIOCOMP Gradient Mate (BIOCOMP, Fredericton, NB, Canada) as previously described (Wang et al., 2009 
Pulse-chase and hERG-chaperone-interaction studies
Pulse-chase and hERG-chaperone-interaction experiments were performed as described (Ficker et al., 2003) . Briefly, HEK/hERG WT cells were starved for 30 min and pulse labeled for 60 min in 100-150 μCi/ml [ 35 S]-methionine/cysteine containing medium. Cells were harvested immediately after labeling or following different chase periods in label-free medium.
Pentamidine was added for 24 h prior to labeling. Cells were lysed in a 0.1% NP40 buffer in the presence of protease inhibitor. Lysates were immunoprecipitated with anti-hERG antibody (Alomone Labs) and collected with Protein G Dynabeads (Dynal, Lake Success, NY).
Immunoprecipitated radiolabeled proteins were separated by SDS-PAGE, and analyzed with a STORM PhosphoImager (GE Healthcare). In pulse chase experiments, image densities of fullyglycosylated (fg) and core-glycosylated (cg) hERG were normalized to the signal of freshly synthesized, cg-hERG protein isolated immediately after radiolabeling at t=0.
To study hERG-chaperone interactions, HEK/hERG WT cells were labeled and chased in the absence or presence of pentamidine as described above. Immunoprecipitations were This article has not been copyedited and formatted. The final version may differ from this version. with rabbit anti-hERG GST antibody and mouse anti-KDEL antibody (Ficker et al., 2003) . The tetrapeptide KDEL, located at the carboxy-terminal sequences of luminal ER proteins, is a common motif expressed in the ER that is well-suited as a compartment marker. For staining, cells were incubated for 2 h at room temperature with secondary anti-rabbit FITC (Jackson Labs, Bar Harbor, ME, USA) and anti-mouse Rhodamine RedX antibody (Jackson Labs). Coverslips were mounted with Vectashield and imaged using a Leica TCS SP2 laser scanning confocal microscope (Leica Microsystems, Wetzlar, Germany).
Data analysis
Data are expressed as mean ± S.E. of n experiments or cells studied. Differences between means were tested using either a two-tailed Student's t-test or single factor analysis of This article has not been copyedited and formatted. The final version may differ from this version.
variance followed by a two-tailed Dunnett's test to determine whether multiple treatment groups were significantly different from control. P-values <0.05 were considered statistically significant.
Results
Pentamidine inhibits hERG forward trafficking. We and others have previously reported that pentamidine reduces cell surface expression of hERG within 24 h in a concentration-dependent manner (Cordes et al., 2005; Kuryshev et al., 2005) . However, whether pentamidine decreases hERG stability directly at the cell surface or, alternatively, inhibits hERG forward trafficking from the ER remained unresolved. To determine hERG surface stability as a function of drug exposure we studied the time course of pentamidine effects by incubating HEK/hERG cells for 0.5-24 h with 30 μ M pentamidine. When analyzed on Western blots (Fig.   1A ), we found that the fully-glycosylated 155-kDa cell surface form of hERG (fg-hERG) decayed in the presence of pentamidine with a half-life of 10.5 h, which compared well to a half-life of about 11 h determined for fg-hERG under control conditions in pulse chase experiments (Ficker et al., 2003) . In marked contrast, fg-hERG decayed much faster with a half-life of 2.4 h on incubation with 0 [K + ] ex , which is known to increase endocytic uptake of hERG channels from the cell surface ( Fig. 1B ; Guo et al., 2009) . The slow reduction of fg-hERG on Western blots was also reflected in electrophysiological recordings, where we measured hERG current densities of 67.1 ± 10.2 pA/pF (n=10) under control conditions, of 69.6 ± 20.8 pA/pF (n=7) following 6 h exposure to pentamidine, and of 4.9 ± 1.7 pA/pF following 24 h exposure to pentamidine (n=6; To confirm independently that pentamidine inhibits hERG forward trafficking, we performed pulse chase experiments to examine hERG maturation in the absence and presence of pentamidine. In these experiments, the appearance of complex or fully glycosylated hERG was used to monitor ER exit and passage of the channel protein through the Golgi apparatus. We found that hERG maturation from the initially synthesized 135-kDa ER resident form to the fullyglycosylated 155-kD form was blocked, while the ER resident cg-form of hERG accumulated in the presence of 30 μ M pentamidine ( Fig. 2A, B ). To test whether inhibition of ER exit was also reflected in an altered subcellular localization of hERG, we co-stained HEK/hERG cells in immunocytochemical experiments with anti-hERG and anti-KDEL (a well-established ER marker) antibodies either under control conditions or following overnight exposure to pentamidine ( Fig. 2C ). While hERG staining could be detected both at the cell surface and in the ER under control conditions, hERG was restricted to the ER on incubation with pentamidine, as expected, when ER export is blocked.
Astemizole rescues pentamidine-induced trafficking inhibition. Astemizole is an
anti-histamine known to directly block hERG channels with high affinity in electrophysiological experiments, where IC 50 values of 6-13 nM have been reported at physiological temperatures (hERGAPDbase; Hishigaki and Kuhara, 2011) . More importantly, however, astemizole has been used previously as a pharmacological chaperone to correct trafficking defects in several LQTShERG mutations located in the transmembrane region of the channel protein, most likely via direct interactions with the universal drug binding site in the conduction pathway (Ficker et al., 2002) . Consequently, we employed astemizole as a conformation-sensitive probe to further dissect inhibition of hERG forward trafficking by pentamidine. Astemizole restored hERG trafficking in the presence of 10 μ M pentamidine half-maximally at a concentration of 335 ± 33 nM (n=3) on Western blots. In the presence of 30 μ M pentamidine, astemizole rescue was halfmaximal at 962 ± 89 nM (n=3) with the rescue-response curve parallel shifted to the right ( Fig.   3A , B). Furthermore, astemizole was able to restore ER export to control levels at both This article has not been copyedited and formatted. The final version may differ from this version. pentamidine concentrations tested, as if pentamidine and astemizole were to compete for overlapping binding sites. To test whether pharmacological rescue would produce functional channels at the cell surface, we also measured hERG currents ( Fig 3C) . Tail current density was 43.5 ± 4.4 pA/pF (n=7) under control conditions and 4.9 ± 1.5 pA/pF (n=6) following overnight incubation with 30 μ M pentamidine. On co-incubation with 30 μ M pentamidine and 5 μ M astemizole, tail current density was increased to 19.3 ± 4.3 pA/pF (n=6) after astemizole had been washed out for 1 hour prior to recording. Since wash-out of a high affinity blocker like astemizole is notoriously difficult and never complete, we additionally determined tail currents densities in HEK/hERG cells incubated solely with 5 μ M astemizole. Under these conditions we measured a current density of 16.4 ± 2.8 pA/pF (n=6) following a 1 hr wash-out of astemizole which was not different from measurements that followed co-incubation with both pentamidine and astemizole. Taken together, our data suggest that pentamidine-induced trafficking inhibition can be almost completely reversed by the pharmacological chaperone astemizole as judged from
Western blots, and that fully functional channels are rescued to the cell surface.
Mutational analysis of pentamidine-hERG interactions.
Guided by our rescue experiments we surveyed a series of mutations in the transmembrane domain of hERG (S1-S6) that replaced negatively charged glutamate or aspartate residues with alanine, because we considered negatively charged amino acid residues putative interaction partners for positively charged pentamidine. Mutations in the S1-S4 voltage sensor domain included hERG 4EC, which removes not one but 4 glutamate residues in the extracellular S1-S2 linker (Fernandez et al., 2005) , hERG D456A, D460A, D466A, D509A, E518A, E519A, D540A and E544A. In the inner pore region (S5-S6) we tested three additional negative charge replacements, hERG E575A, D580A and D591A. We found that none of these mutations affected pentamidine-induced hERG trafficking inhibition (data not shown).
In marked contrast, pentamidine-induced trafficking inhibition was substantially attenuated by hERG F627Y, a unique mutation in the signature sequence of the selectivity filter This article has not been copyedited and formatted. The final version may differ from this version. (Wang et al., 2009; Wang et al., 2007) . Since F627Y promotes channel inactivation (Gang and Zhang, 2006) , we extended our analysis to hERG S641A, a mutation in the S6 transmembrane helix with accelerated inactivation ( Fig. 4B ; supplemental Fig. S2 ) (Bian et al., 2004) , and to hERG S631A, a mutation in the extracellular mouth of the conduction pathway with disrupted inactivation (Zou et al., 1998) . In both instances we found wildtype behavior which suggested that pentamidine effects were not correlated with inactivation gating
Next, we focused on the possibility that astemizole and pentamidine may share overlapping binding sites. We approached this hypothesis in a first set of experiments utilizing bovine ether-a-gogo (bEAG) channels instead of engineered hERG mutants. This is for the following reason: both hERG and bEAG belong to the EAG potassium channel family and show a high degree of sequence homology in the inner pore region (S5-6) where the canonical drug binding site of hERG is located (Warmke and Ganetzky, 1994) . However, bEAG channels are relatively insensitive to block by 'classical' hERG blockers (Ficker et al., 1998) . Similarly, astemizole blocks hERG half-maximally at concentrations of 6-13 nM, while hEAG is about 20 to 30-times less sensitive with an IC 50 value of about 200 nM (Garcia-Ferreiro et al., 2004 ). Thus we speculated that bEAG may be less sensitive to pentamidine-induced trafficking inhibition, if a hERG-like drug binding site were to form an indispensable mechanistic requirement. Indeed, bEAG trafficking was not affected by pentamidine concentrations up to 100 μ M as judged from analysis of fully-glycosylated cell surface channels on Western blots (Fig. 4A, B) . Furthermore, bEAG currents were much less sensitive on long-term exposure to pentamidine than hERG WT channels ( Fig. 4C ).
At this point our structure-function studies directed us towards the universal drug binding site of hERG as a candidate region for pentamidine interactions. The two most important This article has not been copyedited and formatted. The final version may differ from this version. determinants of drug binding to hERG include an aromatic tyrosine (Y652) and phenylalanine (F656) in the S6 transmembrane helix which are complemented by additional residues located at the intracellular mouth of the selectivity filter (Thr623, Ser624, Val625) when high affinity blockers such as astemizole are bound (Mitcheson et al., 2000) . We studied the effects of mutations in three positions, hERG S624, Y652 and F656, to evaluate the effects of perturbations of drug binding on pentamidine-induced trafficking inhibition. When hERG S624A was transiently expressed in HEK cells and exposed overnight to either 10 or 30 μ M pentamidine, fghERG S624A levels were reduced on Western blots to 61 ± 4.5% and 36 ± 5.2 % (n=3), respectively, which was not different from WT levels which were reduced to 61 ± 3.8 and 33 ± 3.9 % (n=5-6; supplemental Fig. S3 ).
Our Western analysis of hERG Y652A revealed an unusual biphasic change in surface expression on overnight incubation with pentamidine, i.e. an initial increase in cell surface hERG Y652A on incubation with 1 μ M pentamidine was followed by a decrease with 10 and 30 μ M pentamidine. In marked contrast, expression of the immature (cg) form of hERG Y652A was augmented in a dose-dependent manner over the entire concentration range studied (supplemental Fig. S4 ). The biphasic behavior of fg-hERG Y652A on Western blots was also reflected in electrophysiological recordings, where tail current density increased from -31 ± 5.0 pA/pF (n=14)
under control conditions to -102.7 ± 19.5 pA/pF (n=4) on overnight incubation with 1 μ M pentamidine, followed by a decrease to -75.3 ± 13.8 (n=11) and -48 ± 6.6 pA/pF (n=14) on incubation with 10 and 30 μ M pentamidine, respectively.
Next, we analyzed a series of point mutations in position phenylalanine(F)656 which is crucial to drug binding in hERG, including substitutions with tryptophan (W), methionine (M), threonine (T), cysteine (C), alanine (A) and valine (V) (Fernandez et al., 2004; Guo et al., 2006) .
In general, it is thought that high-affinity drug binding is correlated with measures of hydrophobicity. Specifically, it has been reported that IC 50 values for several high affinity blockers were increased when F656 was mutated to T, A or V. We transiently expressed all six This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 5A) . We found that substitutions in 656 with T, C, A or V produced channels apparently less sensitive to pentamidine than WT or channels with substitutions of W or M (Fig. 5B) . To correlate changes in surface expression with changes in current expression we also recorded maximal tail current amplitudes at -120 mV under control conditions or on incubation with either 10 or 30 μ M pentamidine ( Fig. 5C ; supplemental previously determined that hERG is present as monomer or dimer in peak P1, while it forms channel tetramers in P2 (Wang et al., 2009 ). Importantly, we could not detect any quantitative differences in the distribution of hERG on sucrose gradients as a consequence of pentamidine exposure. To evaluate the sensitivity of our assay, we also studied a trafficking impaired LQTS2 mutation, hERG A561V (Ficker et al., 2000) . When compared to WT, HERG A561V showed an increase in peak P1 with a concomitant reduction in P2 indicating that assembly of this trafficking-deficient LQTS2 mutant was destabilized (supplemental Fig. S6 ).
Other possible explanations for ER retention include (1) inhibition of chaperone association in the hERG export pathway as described for geldanamycin or (2) drug-induced This article has not been copyedited and formatted. The final version may differ from this version. channel misfolding leading to prolonged hERG-chaperone interactions and ER retention (Ficker et al., 2003) . Consequently, we studied interactions of hERG WT with two major cytosolic chaperones, Hsp/c70 and Hsp90, immediately after synthesis, or following a chase period of 6 h in HEK/hERG cells cultured under control conditions or following overnight incubation with pentamidine ( Fig 7A) . Quite surprisingly, we did not find any difference in the formation and stability of either hERG/Hsp/c70 or hERG/Hsp90 complexes in the presence of pentamidine (Figs. 7B) . Thus, pentamidine-induced inhibition of hERG forward trafficking may not be mediated via cytosolic chaperones.
Finally, inhibition of ER export has often been linked to increased channel ubiquitination (Ficker et al., 2003; Gong et al., 2005) . Consequently, we measured hERG ubiquitination under control conditions or following overnight exposure to 30 μ M pentamidine. To this end, we expressed hERG WT together with HA-or His 6 -tagged ubiquitin. Incubation with the Hsp90 inhibitor geldanamycin known to increase hERG ubiquitination was used as positive control.
Following immunoprecipitation with anti-hERG antibody immunoprecipitates were blotted with either anti-hERG or anti-HA antibody to detect multi-ubiquitinated hERG proteins. We found that on Western blots, hERG ubiquitination was increased in the presence of geldanamycin, but not pentamidine (Fig. 8 ) which actually decreased hERG ubiquitination slightly.
Analysis of pentamidine effects on native hERG/I Kr currents in cardiomyocytes.
In addition to our experiments in a heterologous expression system, we have also studied pentamidine effects on native ERG protein and I Kr currents in murine HL-1 cardiac myocytes (Claycomb et al. 1998 ) as well as in neonatal rat ventricular myocytes (NRVMs). To assess for pentamidine-induced inhibition of channel surface expression, we incubated HL-1 cells overnight with either 1 or 10 µM pentamidine. On Western blots we found that pentamidine suppressed expression of fully glycosylated full-length mERG1a protein as well as of an N-terminal splice variant, mERG1b, present in HL-1 myocytes in a concentration-dependent manner. In contrast, Kv1.5 expression was not altered by incubation with pentamidine (Fig. 9A) . Reduction of cell This article has not been copyedited and formatted. The final version may differ from this version. were activated on return to -50 mV that specifically reflect ERG-mediated I Kr (see arrows in Fig.   9B ). Maximal I Kr density was reduced from 3.9 ± 0.6 pA/pF (n=14) under control conditions to 0.6 ± 0.1 pA/pF (n=5) following overnight incubation with 10 µM pentamidine (Fig. 9C ). When I Kr was blocked by application of 5 µM E4031, residual I K currents were analysed at the end of depolarizing test pulses to +60mV. In contrast to I Kr , I K current density was not significantly affected by 10 µM pentamidine. We measured 8.8. ± 2.7 pA/pF (n=7) under control conditions and 11.8 ± 3.6 pA/pF (n = 6) on incubation with 10 μ M pentamidine.
Furthermore, we have studied pentamidine effects on native I Kr /rERG channels in cultured NRVMs. Overnight incubation with pentamidine (30 μ M) suppressed the fully glycosylated (fg) cell surface form of rERG on Western blots. Importantly, pentamidine effects could be reversed on co-incubation with 3 μ M astemizole as expected from our experiments with HEK/hERG cells (Fig. 9D ). To complement our Western analysis in NRVMs, we also monitored I Kr current density as a function of pentamidine exposure. NRVM I Kr currents were isolated in symmetrical Cs + -solutions and elicited using 350ms depolarizing test pulses from a holding potential of -80 mV (Fig. 9E) . Maximal I Kr tail current amplitudes measured on return to -80 mV were reduced from -16.5 ± 3.1 pA/pF (n=5) under control conditions to -6.8 ± 1.6 pA/pF (n=5) following overnight incubation with 30 μ M pentamidine (Fig. 9F ).
Discussion
Pentamidine is unusual in that it targets the cardiac potassium channel hERG by reducing its surface expression slowly over time which delays cardiac repolarization and contributes to prolongation of the QT interval on the electrocardiogram (Cordes et al., 2005; Kuryshev et al., 2005) . To contrast this unique mode of action with direct hERG blockade, pentamidine has been classified in the past as a hERG trafficking inhibitor which tacitly implied disruption of forward trafficking from the ER as mechanism. However, channel endocytosis in combination with accelerated degradation has emerged more recently as an alternative mechanism used by proarrhythmic compounds to control hERG surface expression. For example, it has been shown that probucol, a cholesterol lowering drug causing acLQTS, increased endocytic hERG uptake from the cell surface (Guo et al., 2011) . A similar increase in endocytosis has been described upon exposure of hERG to low extracellular potassium concentrations (Guo et al., 2009 ). To clarify the cellular and molecular mechanisms that control hERG surface expression in the presence of pentamidine, we have investigated the time course of pentamidine effects on Western blots and in electrophysiological current recordings. In contrast to fast changes in surface expression seen with probucol or on incubation with 0 [K + ] ex , short-term effects of pentamidine were minimal over several hours and consistent with a half life of about 10-11 h determined for WT under control conditions (Ficker et al., 2003) . Importantly, lack of short-term effects cannot be attributed to slow access of dicationic pentamidine to the cell interior, because acute inward rectifier block was established within 5-10 min following extracellular application of pentamidine (Cordes et al., 2005; de Boer et al., 2010; Kuryshev et al., 2005) . Furthermore, we have shown that newly synthesized hERG did not reach the Golgi apparatus using pulse chase experiments and that hERG immunostaining was restricted to the ER in the presence of pentamidine. Thus, we conclude that pentamidine disrupts exclusively hERG forward trafficking from the ER.
This article has not been copyedited and formatted. The final version may differ from this version. To further dissect inhibition of forward trafficking by pentamidine at the mechanistic level, we have used the pharmacological chaperone astemizole as a conformation-sensitive probe.
Astemizole has been used previously to correct conformational defects in mis-folded, trafficking deficient LQTS hERG mutants, while folding and trafficking of wildtype channels were not affected (Ficker et al., 2002) . In addition, astemizole rescue was restricted to mutations in the transmembrane domain of the channel protein , and relied on binding to phenylalanine656 in the universal drug binding site of hERG (Ficker et al., 2002) . By analogy, we speculated that successful rescue experiments with astemizole may help us to uncover and localize pentamidine-induced conformational defects in hERG. In fact, astemizole restored hERG trafficking in the presence of pentamidine indicating first of all that a 'general' shut down of protein export from the ER was not the root cause for pentamidine-induced trafficking inhibition. This was not unexpected, because pentamidine reduced hERG surface expression specifically among several other major cardiac ion channels tested . More importantly, however, successful astemizole rescue suggested an induced conformational defect in the transmembrane region of hERG and provided first hints that astemizole and pentamidine may interact in a competitive manner.
Several predictions from rescue experiments could be verified directly in our mutational analysis. First of all, pentamidine effects were attenuated by hERG F627Y, a mutation in the narrow selectivity filter. Because the amino acid residue in hERG627 does not project in the direction of the conduction pathway, it is neither accessible to dicationic pentamidine nor astemizole. However, a tyrosine residue in hERG627 may provide additional hydrogen bonds to a cuff of aromatic residues that stabilizes the selectivity filter and ultimately the entire channel protein (Doyle et al., 1998) . This may also explain why hERG F627Y attenuates not only pentamidine effects, but also trafficking defects induced by cardiac glycosides or on exposure to low K + (Massaeli et al., 2010; Wang et al., 2009 ).
This article has not been copyedited and formatted. The final version may differ from this version. Secondly, pentamidine effects were reduced by mutations in position hERG F656 that retained relatively normal biophysical properties but decreased sensitivity to direct hERG block (Fernandez et al., 2004) . This suggested to us that a binding event similar to the binding of direct blockers in native channels may render hERG trafficking deficient. For example, mutation of F656 to Tyr, Trp or Met did not affect pentamidine-induced trafficking inhibition in line with only modest effects on direct hERG block. In contrast, mutation of F656 to Thr, Cys or Val all of which are relatively insensitive to drug block strongly reduced trafficking inhibition. We also noted differences in the requirements for trafficking inhibition and drug binding. For example, mutation of F656 to Ala seemed to attenuate trafficking inhibition on Western blots but not in current recordings, while it has been shown to decrease direct hERG block very strongly.
Similarly, the aromatic side chain in position 652 which is required to maintain drug sensitivity for high-affinity blockers such as MK-499 or cisapride (Mitcheson et al., 2000) , was less important for pentamidine induced trafficking inhibition, since hERG Y652A retained at least some sensitivity to pentamidine.
Differences between the mechanisms of direct channel blockade and pentamidineinduced trafficking inhibition were anticipated, since terminally folded hERG channels are not blocked by pentamidine with high affinity in acute experiments (Cordes et al., 2005) . In fact, the affinity of pentamidine for direct hERG block at physiological temperature was approximately 300 μ M, while hERG trafficking was inhibited half-maximally by only 8 μ M pentamidine . For this reason, we propose that pentamidine binds to an emerging This leaves us with the important question of how ER export of hERG is curtailed by cellular quality control mechanisms in the presence of pentamidine. Obviously, the proposed interactions of pentamidine with residues in transmembrane helix S6 could have destabilized channel assembly producing incompletely assembled proteins that are retained in the ER.
However, we showed that hERG assembly into tetramers was not disturbed on long-term exposure to pentamidine. Alternatively, pentamidine could have arrested hERG in a slightly aberrant tetrameric conformation that is recognized by cellular chaperones. However, to our surprise association with two crucial cytosolic chaperones, Hsp/c70 and Hsp90, was not altered in the presence of pentamidine. While it is still possible that interactions with another chaperone system may be targeted by pentamidine, we consider this possibility unlikely, because altered chaperone interactions are most often accompanied by an increase in channel ubiquitination and degradation. Again, this could not be shown. In marked contrast, channel ubiquitination was decreased, and immature, ER resident hERG accumulated in the presence of pentamidine (see Fig. 2B ). Based on these observations, we suggest that long-term exposure to pentamidine may uncover a chaperone-independent quality control step for hERG. We believe that in the presence of pentamidine hERG matures to a point where chaperone systems disengage and where channels are subjected to a last quality check that does not focus on conformational integrity. Instead, channel proteins may be surveyed for exposed ER retention or export signals similar to what has been described for various inward rectifier channels.
Taken together, we have shown that in the presence of pentamidine hERG is no longer exported from the ER. Thus, inhibitors of hERG surface expression can be grouped in at least two functional classes: those that reduce hERG surface expression by increasing channel endocytosis, and those like pentamidine or arsenic trioxide that prevent channel export from the ER and are best characterized as hERG trafficking inhibitors. Furthermore, we provide the first This article has not been copyedited and formatted. The final version may differ from this version. (Guo et al., 2011; Wu et al., 2011) , which are thought to mediate changes in hERG surface expression via effects on the composition of lipid rafts surrounding the channel protein. The reliance of pentamidine on hERG specific amino acid residues may also provide an answer to its specificity and may explain why pentamidine effects are restricted to ER export, because the native conformation of hERG which is present in post-ER compartments binds pentamidine with much lower affinity only.
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